Index

Abelson, J., 254–255
Academia Platonica (Neoplatonic Florentine Academy), 218
Academy of Medical Sciences (AMS, UK), 358–359
  goals and mission of, 3–5
access to healthcare
  benefit sharing and, 154–156
  orphan drug research and, 62
  solidarity and, 59–61
accountability
  governance and, 123–124
  institutional decision-making and, 211
  medical device failure and, 163–164
  non-traditional medicine and, 299
actor-networks
  Big Data research and, 257–259
  global health emergency guidelines and, 316–317
adaptive governance principles
  Big Data research and, 257–265
  evolution of, 257–259
  structures and processes in, 263–265
  visibility, 264–265
adaptivity, in health research governance, 259–260
Addgene company, 142–144
Additional Protocol (2005), 105–106
add-on services in reproductive medicine
  ethical issues with, 375–377
  patient choice dynamic in, 380
  regulation of, 377–379
  risks of, 380–381
advanced therapies
  Argentinian regulation of, 324–331
  regenerative medicine and, 324
advertising of innovative intervention, oversight of, 292–295
Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
advisory committees
  adaptive governance and, 263–265
  Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
  in bioethics, 220–222
  Bioethics Advisory Body, 284–285
  future of health research regulation and, 222–224
  health policy advice and, 215–216
advocates, public engagement with, 117
affected public
  classification of, 117
  data-intensive health research and, 118–119
AFIRRM oversight model
  Big Data research and, 259–260
  future challenges for, 265
  implementation of, 260–263
agency, automated healthcare regulation and, 268–269, 273
aggregated data, individual discrimination and stigmatisation and, 242
aggregative theories, public interest and, 240
Aitken, Mhairi, 14, 70–71, 112–129
Alder Hey organ retention scandal, 212–213
Aldrick, Philip, 270
Allen, A. L., 75
All of Us initiative, 103–104
All Party Parliamentary Group on Surgical Mesh Implants, 162–165
alternative medicine
  history and evolution of, 296–298
  research regulation of, 296–305
  uncertainty of knowledges and practices and, 303–304
  as *in vitro* add-on, 375–377
Althusser, L., 251–252
animal research
  embryo research and, 356–364
  human material in animals and, 358–359
  interspecies research and, 356–364
  in neuroscience, 310–312
  regulation and oversight of, 359–362
  shifting regulatory boundaries in, 362–363
  vulnerability issues in regulation of, 363–364
Animals Containing Human Material (Academy of Medical Sciences), 358–359
Annas, George, 352
Ansell, C., 124–125, 128–129

anticipatory knowledge
  emerging science and technology oversight and, 397–399
  in global health emergency research, 322–323
  participatory health governance and, 285–286
anti-science politics
  health policy formation and, 216–218
  health research regulation and, 222
  traditional and non-conventional medicine and, 301–302
Argentina
  agricultural strength and health fragmentation in, 324–325
  cell therapy research governance in, 325–326
  construction of research governance in, 328–329
  current health legal/regulatory framework in, 330–331
  health research regulation in, 324–331
Arnstein, S. R., 114, 116
ArthritisPower network, 126–127
artificial intelligence (AI)
  best practices guidelines and, 175
  co-dependent human-technology embodiment and, 383–384
  continuous learning, research-therapy divide and, 277–286
  existence conditions and, 272
  as medical device, 277–286
  regulatory responsibility and, 271–274
  voluntariness in, 107–108
assisted reproduction, human germline research and, 348–350
Association of University Technology Managers, 142–143
Australia
  cloning research in, 347–348
  evidence-informed health policy in, 216–218
Australian Academy of Learned Societies, 220
authority. *See* governance
autologous mesenchymal stem cell case study, clinical innovation oversight and, 290–292
automated healthcare regulation
  balance of interests in, 267–268
  moral development and agency and, 273–274
  regulatory responsibility and, 271–274
  self-development and agency issues and, 273
  stewardship responsibilities in, 268–269
autonomy
  artificial intelligence and, 271
  disclosure of research findings and, 233–234
  health research ethics guidelines, 27–29
  health research regulation and, 13–15
  individualistic conceptions of, 29–30
  informed consent and, 104–105, 108–109
  non-invasive prenatal testing and, 267–268
  privacy and, 246
  relational conceptions of, 27–36
availability heuristic, risk-benefit analysis and, 134–135
Aviesan initiative, 103–104

Baier, A., 84–85
balance of interests
  automated healthcare regulation and, 272
  health research regulation and, 268
Ballantyne, A., 23–24
Barbazza, E., 123–124
Barber Surgeons of Edinburgh, 218
Barsdorf, Nicola, 51–52
Bea, Sara, 356–364
Beauchamp, T. L., 39, 169–170
beliefs, facts and, health policy and, 217
Belmont Report (1979), 7–8
  autonomy guidelines in, 27–29
  social values, 46–47
  vulnerability guidelines in, 17–18, 33
beneficence
  autonomy guidelines and, 27–29
  informed consent and, 104–105
  proportionality and, 39
benefit analysis
  risk-benefit analysis and, 132–134
  social value and, 53–54
benefit evaluation, social value and, 54
benefits, defined, 149–151
benefit sharing
  challenges to, 154–156
  common heritage argument for, 150–151
  data access agreements and, 191
  descriptive argument for, 150–151
  governance frameworks for, 151–153
  health research regulation and, 148–157
  history and rationale for, 149–151
  procedures for, 153–154
benefit treatment, social value and, 54
Bennet, C. J., 241–243
Bennett, Alan, 145–146
Beresford, P., 121–123
Berger, M., 251–252
best practices
  displacement of traditional medicine in, 299–301
  examples, 192–195
  health research regulation, 173–175
  in vitro fertilisation and, 374
Big Data research. *See also* data-driven research
  adaptive governance in regulation of, 257–265
  analytical techniques in, 257–259
  deliberative participatory practices and, 125–126
  effective governance of, 260–263
  participatory governance of research and, 121
  patient and public involvement in, 121–123
  regulatory scholarship on, 257–259
  structures and processes in, 263–265
  systemic oversight framework for, 259–260
  uncertainty in, 262–263
  voluntariness in, 107–108
biobanks
  disclosure of research findings and role of, 233
  regulation of, 6–7
Biobricks Foundation, 142–143
bioethics
  advisory committees, 220–222, 284–285
  French law on, 264
  medical device failure and, 162–165
Bioethics (journal), social value debate in, 51–52
biosecurity regulations, in Argentina, 324–325
blaming, medical device failure and, 163–164

Blasimme, Alessandro, 217
blinded trials, evidence-based medicine and, 298–299
Blueprint for Dynamic Oversight of Emerging Science and Technologies, 397–399
bottom-up participation
  participatory health governance and, 124–125
  principles-based regulation and, 259
Boyd, Ian, 217
Bracken-Roche, D., 20–22
Bradwell, P., 118
Brandeis, S. D., 75
Brassington, Iain, 14–15
Braun, K., 112–113, 117
Breakthrough Device designation (FDA), 278–281
Briggs (Lord Justice), 245–246
bright line ideology, human germline research and, 349–350
broad consent principle, 103–104
Broad Institute, 143–146
Brownsword, Roger, 266–274
Bryant, R., 159–160
burdened populations, solidarity in health research for, 59–61
Burgess, Michael M., 14, 69–70, 248–256
Bush, George W., 216–218, 222–223

Caldicott Principles, 167–168
Caldicott Report, 248–249
Canada
  autonomy guidelines in, 27–29
  ethics review in, 200–201
  genetics research regulation in, 337–340
Canadian Academy of Engineering, 219–220
Canadian Academy of Health Sciences, 219–220
Canadian Tri-Council, 19–20
capacity perspective
  cooperative tool for capacity building, 153
  participatory governance and, 127
  vulnerability and, 24–25
  in vulnerability research, 20–22
Care Act 2014 (UK), 182–184
care.data scheme (UK), 118–119, 122–123, 248–249
Carroll, T., 159–160
Carter, P., 69–70
Categorical Imperative (Kant), 78–79
cell therapy research, Argentinian governance of, 325–326
centralised supervision and coordination, participatory governance and, 128–129
Chambers, Simone, 252–253
Chan, Sarah, 344–355
Charities Commission (UK), 301–302
children, relational autonomy of, 34–36
Childress, J. F., 39, 169–170
chimeric organisms
  interspecies research and, 357–358
  research guidelines involving, 360
  shifting regulatory boundaries in research on, 362–363
  vulnerability issues in research on, 363–364
China, human gene editing in, 337–341, 351, 353
Chuong, Kim H., 121–129
circumstances, vulnerability and, 23–24
citizens
  identity interests in health research regulation and, 397–399
  public engagement with, 117
citizens' forums, participatory health systems governance and, 125–126
clarity of purpose
  participatory governance and, 128
  public engagement and, 118–119
clinical decision support (CDS) software
  AI/ML software, 278–281
  research-therapy divide and, 277–278
clinical equipoise, component analysis and, 135–136
clinical research
  innovation in marketplace and, 287–295
  social value in, 51–52
ClinicalStudyDataRequest, 192–195
clinical trials regulatory paradigm
  economics of clinical guidelines and, 301–302
  evidence-based medicine and, 298–299
  medical device trials, 279–281
  pay-to-participate clinical trials and, 290–292
  regulatory research and, 5–9
  social value and, 52
  traditional and alternative medicines and, 299–301
clinical utility of information, disclosure of research findings based on, 231
Clinton, Bill, 221–222
Cloatre, Emilie, 296–305
cloning
  ethical review of, 221–222, 335–336
  international health policy frameworks on, 340–341
  legislation involving, 347–348
  terminology and definitions of, 347–348
clustered regularly interspersed palindromic repeats (CRISPR) patents, 143–146
  ethical issues in, 267–268
  human gene editing regulation, 335–336
  human germline research and, 345–346
co-dependent human-technology embodiment
  enhancement innovations and, 383–384
  identity and integrity issues in, 384–386
coercive isomorphism, 213
cognitive bias, risk-benefit analysis and, 134–135
cognitive disability, relational autonomy and, 34–36
Colbert, Jean-Baptiste, 218
Coleman, Carl H., 14, 130–138
Coleman, S., 119–120
collaborative licensing, 144–145
  patent regulation and, 144–145
collaborative research
  Argentinian-University of Edinburgh research governance collaboration, 325–326
  Big Data research and, 257–259
  categories of, 82–83
  clinical innovation oversight and, 289–290
  data sharing collaborations, trust in, 87–89
  human germline research, 350–352
  in interspecies research, 363–364
  in neuroscience, 308
  participatory health governance and, 124–125, 285–286
  patent rights and, 141
  trust and, 81–82

https://doi.org/10.1017/9781108620024.049 Published online by Cambridge University Press

collective interests
health research regulation and, 7, 14
public expertise mobilisation and, 253–255
commercialisation of research
benefit sharing and, 154–156
data access and, 192–195
group vulnerability and, 97
health research regulation and, 7
common good
automated health regulation and, 268–269
privacy and, 78
common heritage argument for benefit sharing, 150–151
common interest theory
group privacy and, 241–243
public interest and, 240–241
Common Rule. *See* Federal Policy for the Protection of Human Subjects (Common Rule, US)
common value theory, 240–241
communitarian approach
automated health regulation and, 268–269
benefit sharing, 153–154
global health emergencies and, 319–320
informed consent and, 108–109
institutional decision-making and, 210
risk-benefit analysis and, 138
community advisory boards, participatory health systems governance and, 125–126
community values. *See* social value
Compangie du Gai Sçavoir, 218
comparative effectiveness research, minimal risk principle and, 199–200
competency
autonomy and, 31
informed consent and, 106
competition, patent regulation and, 140–141
complementarity, governance structures and, 264
complementary and alternative medicine (CAM). *See* alternative medicine
component analysis, risk-benefit analysis using, 135–136
confidentiality
in Big Data research, 123
duty of confidence and, 245–246
in neuroscience research, 308
privacy and, 79
public interest guidelines and, 67–70
Confidentiality Advisory Group (CAG) (HRA, UK), 67–70, 212–213
Confronting the Liminal Spaces of Health Research Regulation project, 3
consent. *See* informed consent
consent or anonymise regulation model, 4
consent to contact policies, 201–202
consultation, public engagement through, 115–116
consumerist approach
autologous mesenchymal stem cell case, 290–292
clinical innovation and intervention and, 289
innovation oversight and limits of, 292–295
medical device regulation and, 386–389
misinformation about reproductive medicine and, 379
non-traditional medicine and, 299
patient and public involvement and, 121–123
in vitro fertilisation and, 375–377
consumers, public engagement with, 117
context
in adaptive governance, 262
in global health emergency guidelines, 316–317
health research regulation and role of, 275–276
in human germline research, 348–350
of institutions, 207–208
proportionality and, 37–38
rule-based and practice-based health regulation and, 172–173
Contreras, Jorge, 141–142
controlled access, data-driven research, 190–191
Convention for the Protection of Individuals with regard to Automatic Processing of Personal Data (Council of Europe), 243–245
Convention on Biological Diversity (CBD) (1992), 149
cooperative practice, human germline research, 350–352
cooperative tool for capacity building, benefit sharing and, 153
co-optation, participatory governance and, 127
costs of health research, solidarity on, 59–61
Council for International Organizations of Medical Sciences (CIOMS), 18–20
benefit sharing guidelines and, 151–153
global health emergency guidelines and, 316–317, 320–322
guidelines, 47–49
health practices guidelines, 173–175
informed consent and, 105–106, 200–201
reasonable availability model of, 152–153
risk-benefit analysis guidelines, 137
social value in health research regulation and, 46–47, 49–51, 199–200
on third-party risks, 130–132
Council of Canadian Academies (CCA), 219–220
Council of Europe
data protection law and, 243–245
genetics research regulation and, 340–341
informed consent and, 105–106
Council on Health Research for Development (COHJRED), 85–86
COVID-19 pandemic
health practices guidelines and, 173–175
research exceptionalism and, 318–320
credibility tactics, participatory governance and, 127
Crick, Bernard, 96
criminal law
genetics research regulation and, 337–340
human embryo research and, 358–359
physical integrity and identity in, 385–386
crisis research
global health emergency guidelines and, 316–317
human gene editing regulation and, 335–336
risk assessment in, 199–200
social value of, 317–318
criticism, of research ethics, 200–201
cross-border data sharing, in Big Data research, 123

cultural issues
disclosure of research findings and, 233–234
interspecies biomedical research regulations and, 362–363
medical device failure and, 163–164
privacy and, 241–243
culturally significant information, protection of, 242n.23
Cunningham-Burley, Sarah, 14, 112–129
Curran, William, 181–182
cyborg perspective, enhancement innovations and, 383

D'Amour, D., 83
data access
agreements, 191
centralised access, genotype/phenotype database, 193
challenges and future directions, 195–196
governance of, 187–196
harmonisation of policies and processes in, 196
independent, interdisciplinary access, 193–194
multi-study access, EGA, 192
oversight coordination, 195–196
producers' rights and interests and, 194
resources, effectiveness and efficiency in, 195
tiered access, International Cancer Genome Consortium/25K Initiative, 193
transparency and reflexive governance, 194–195
Data Access Committees (DACs), 188–189
adaptive governance and, 263–265
controlled *vs.* open access data and, 190–191
monitoring of data use and, 191–192
multi-study access, EGA, 192
oversight coordination, 195–196
resources, effectiveness and efficiency in, 195
data-driven research. *See also* Big Data research
automated healthcare regulation and, 270
controlled *vs.* open access data, 190–191
current and future trends in, 198–199
disclosure of research findings and, 231–234
duty of confidence and privacy of, 245–246
EGA and, 192
group privacy protections in, 243–245
health research regulation and, 7–8
informed consent and, 103–104
integrity and ethics protections, 188–189
monitoring of data use and, 191–192
in neuroscience, 308
privacy rights and, 75–77
producer rights and interests in, 189–190
public engagement in, 116, 118–119
public perceptions of, 217
relationality in, 59–61
rules-based *vs.* practice-based approaches in regulation of, 170–171
subject rights and, 188–189
trustworthiness of research governance and, 248–249
value and social values in, 394–396
Data Protection Act 2018 (DPA, UK)
enactment of, 69
HRR community lobbying and, 71–72
neuroscience research and, 310–312
research governance and, 167–169
Data Protection Regulation 2016/679 (GDPR) (EU), 75–77
data sharing
governance frameworks for, 187–188
informed consent and, 105–108
in neuroscience research, 308
participatory learning in regulatory governance and, 284–285
privacy protection and, 73–74
public engagement and, 116
trustworthiness in, 87–89
Datta, A. K., 376
Davidson, S., 115–116
Dawson, A., 91, 97
decision-making
accountability and risk aversion issues in, 211
central objectives in, 208–209
disclosure of research findings for purposes of, 231
in global crisis emergencies, 317–318
health research regulation and, 99–101
inclusion and equality in, 127
institutional influences on, 205–214
institutional structure and composition and, 209–211
path dependencies and historical influences in, 212–213
privacy in, 75–77
public interest and, 240–241
public *vs.* private duties in, 211
social value and, 54
Declaration of Alma Ata (1978), 299–301
Declaration of Chiang Mai, 300
Declaration of Helsinki
autonomy guidelines in, 27–29
benefit sharing in, 151–152
group access to research participation in, 172–173
informed consent in, 105–107
post-trial obligations in, 152–153
social value in, 46–47, 52–53
vulnerability guidelines in, 18, 90–91
Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks, 103–104
De Cleen, B., 251–252
deep learning, medical devices and, 281
deferred consent, 107–108
deficit model of public understanding, 112–113
Degeling, C, 117
deliberative practices
diversity theory and, 252–253
participatory health governance and, 124–126
public expertise mobilisation and, 248–256
Delphi policy study, 397–399
democratic approach, patient and public involvement and, 121–123
De Novo premarket review process (FDA), 278–281
deontological theory, privacy and, 78–79
descriptive argument for benefit sharing, 150–151
diabetic retinopathy, software as medical device for diagnosis of, 278–281
dialogue, public engagement and role of, 119–120

digital consent technology, 110
DiMaggio, P., 210
direct benefit
  in RCTs, 133
  social value as, 49–51, 53–54
disaster research
  global health emergency guidelines and, 316–317
  public engagement in, 319–320
  risk assessment in, 199–200
  social value of, 317–318
disclosure of research findings
  criteria for disclosure, 231
  ethical issues linked to, 229–238
  guidelines and recommendations about, 230–231
  informed consent and, 107
  narrative function of results, 235–236
  participant's interests and, 234–235
  physical integrity and identity and, 385–386
discourse ethics, privacy and, 79–80
discrimination, in vulnerability research, 20–22
distributed responsibility, governance and, 123–124
diversity, public expertise mobilisation and, 253–255
Dixon-Woods, Mary, 179–180
Dove, Edward S., 30–31, 34–35, 99–101
downstream research, national policy frameworks for genetics and, 337–340
duress, informed consent and, 107–108
duty of care, disclosure of research findings and, 233
duty to participate principal, disclosure of research findings and, 234–235
Dworkin, Gerald, 29–30
Dworkin, Ronald, 272
dynamic consent, 110, 248–249

Ebola outbreak
  experimental interventions and vulnerability in, 92–93
  randomized controlled clinical trials in, 132–134
  unregistered interventions in, 319
Eckstein, Lisa, 231
EC Regulation 141/2000, 62–63
Editas company, 143–146
Edwards, Robert, 373–374
effectiveness of medical devices, marginalised focus on, 162–165
efficacy
  social value and estimation of, 53–54
  in traditional medicine, research on, 299–301
egalitarian diversity and inclusiveness, 252–253
Egelie, Knut, 143–144
Eisenberg, Rebecca, 141
electronic signatures, informed consent and, 110
Emanuel, E., 46–47, 180–181
empowerment
  participatory health governance and, 124–125
  public engagement and, 116
enforceable norms, solidarity and, 58–59
engagement, proportionality and, 44–45
enhancement innovations, development of, 383–384
epistemic injustice, relational autonomy and, 35–36
epistemic integration, medical device failure and, 165–166
Epstein, S., 127
equality
  diversity theory and, 252–253
  non-invasive prenatal testing and, 267–268
Ethical and Policy Issues in International Research (National Bioethics Advisory Commission), 151–152
ethical issues in health research
  autonomy guidelines, 27–29
  benefit sharing and, 151–153
  in Big Data research, 123
  bioethics advisory committees, 220–222
  chimeric research oversight and guidelines and, 359–362
  data protections and, 188–189
  disclosure of research findings and, 229–238
  enhancement innovations and, 383
  ethical approvals process and, 307–309
  ethical licensing, 145–146
  evaluation of regulatory changes and, 202–203
  exemption for types of research, 200–201
  future directions in, 182–185
  genome-editing and, 267–268
  global health emergencies and, 315–323
  health policy formation and, 217–218
  human-technology embodiment and, 384–386
  incidental findings and, 229–230, 309–310
  interspecies research, 357–358
  learned and academic societies' influence on, 220
  learning healthcare systems and, 391–394
  Learning Health Research Regulation System and, 394–396
  net risk test and, 136–137
  neuroscience and, 304, 310–312
  participants' interests and needs and, 234–235
  placebo controls in evidence-based medicine and, 299
  politics and, 92–93
  prenatal testing and, 267–268
  process simplification and harmonisation and, 200–201
  protection of culture and, 242n.23
  randomized controlled clinical trial and, 132–134
  regulatory design and, 182–184
  regulatory process and, 178–180
  relational autonomy and, 30–33
  reproductive medicine and, 375–377
  research integrity and, 188–189
  review as regulatory process in, 178–180
  review of, 177–186
  risk identification and, 130–132
  standardisation of review processes, 182–184
  vulnerability guidelines, 17–18
  in vulnerability research, 20–22
ethical licensing, 145–146
Ethics Advisory Board (US Dept. of Health, Education and Welfare), 366–368
Ethics Guidelines for Trustworthy AI (EC), 271
Ethics Review Committee (WHO), 320–322
The Ethics of Research Related to Healthcare in Developing Countries (Nuffield Council on Bioethics), 151–152
EU Directive 95/46/EC, 167–168, 171

EU Directive 2001/20/EC, 200–201
EU Directive 2004/24/EC, 300–301
EU Regulation 2017/745, 382–383
EU Regulation 2017/746, 382–383
Europe, health research regulation in, 1
European Commission
  benefit sharing guidelines, 154–156
  Guidelines for Trustworthy AI, 175
  risk-benefit analysis guidelines, 137
European Convention on Human Rights (ECHR), 74–75, 245–246
European Court of Human Rights, 75, 245–246
European Directive on Traditional Herbal Medicine Products (THMPD), 297–298
European General Data Protection Regulation, 105–106
European Genome-phenome Archive (EGA), 192
European Group on Ethics in Science and New Technologies to the European Commission, 151–152
European Medicines Agency (EMA)
  advanced therapies regulation and, 324
  Argentinian regulatory harmonisation with, 328–329
  regulatory science and, 394
  reproductive medicine add-on services regulation and, 377–379
European Open Science Cloud (EOSC), 7–8
European Union (EU)
  Data Protection Regulation 2016/679 (GDPR), 75–77
  data protection regulation in, 67–70, 167–169, 171, 243–245
  medical device approvals by, 160–161
  medical device regulation in, 386–389
  regulatory regime in, 14, 56
  traditional and herbal medicine regulation in, 300–301
European Union Clinical Trials Directive, 6–7, 130–132, 199–200, 340–341, 347–348
evidence-based healthcare. *See also* non-evidence-based medicine
  Big Data research and, 257–259
  economics of clinical guidelines and, 301–302
  health policy formation and, 216–218
  learned and academic societies' evaluation of, 220
  norms of evidence and, 303–304
  placebo controls and, 298–299
  risk-benefit analysis and ethics review and, 137–138
  traditional and alternative medicines and, 296–305
excessive risk, risk-benefit analysis and, 136–137
exclusion criteria
  proportionality and, 40
  in vulnerability research, 20–22
existence conditions, automated healthcare regulation and, 272
expectations in health research
  Argentinian regulation of, 327–328
  failure and, 159–162
  neuroscience and, 308–309
  reproductive immunology mythology and, 376–377
  reproductive medicine and role of, 374
experimental interventions
  global health emergencies and, 318–320
  vulnerability and, 92–93
experts and expertise
  evidence-based medicine and, 298–299
  future of health research regulation and, 222–224
  health policy advice and, 215–224
  learned and academic societies, 218–220
  mobilisation in health research regulation of, 248–256
  representation and inclusiveness issues in, 251–253
explicability, artificial intelligence and, 271
exploitation
  group vulnerability to, 93–95
  vulnerability in health research and, 91–92
externalist perspective, relational autonomy and, 31
external validity, in RCTs, 133

facilitative leadership
  participatory governance and, 128–129
  proportionality and, 42–43
failure in health research
  expectations and, 159–162
  history of, 158
  legal interpretations and constructions of, 161–162
  risk assessment and prevention, 158–166
  systemic causes of harm and, 162–165
  values failure, 395
failure of care data, public interest in HRR and, 69–70
fair benefits model, benefit sharing and, 153
Fairmichael, F., 395
fairness
  artificial intelligence and, 271
  non-invasive prenatal testing and, 267–268
fair participation, global health emergency research and, 318–320
Federal Advisory Committee Act (US), 220–221
Federal Policy for the Protection of Human Subjects (Common Rule, US), 46–47, 182–184, 199–201, 223
Federal Regulations on Research With Human Participants (US), 130–132
federal science advisor, 222–223
feedback policies
  disclosure of research findings and, 231–234
  ethical responsibilities in, 236–238
  participants' interest and, 234–235
Feeney, Oliver, 143–144
fertility medicine. *See in vitro* fertilisation; reproductive medicine
fictional man paradigm, public interest litigation and, 69
final cause/objective, of institutional decision-making body, 208–209
Financial Services Authority (FSA, UK), 257–259
Fineman, M. A., 19
first-order proportionality, defined, 37–38
Fish, Stanley, 210
510(k) pathway, medical device trials, 279–281
Flear, Mark, 158–166
flexibility, in health research governance, 259–260
Foley, T., 395
follow-on research, non-exclusive research tool licensing and, 142–143
Food, Drug and Cosmetic Act (US), medical device definition in, 278–281

https://doi.org/10.1017/9781108620024.049 Published online by Cambridge University Press

Food and Drug Administration (FDA, US)
advanced therapies regulation and, 324
Argentian regulatory harmonisation with, 328–329
clinical decision support software and, 277–278
IDx-DR AI diagnostic system approval by, 278–281
medical device approvals and, 160–161
minimal risk principle in regulations and, 199–200
politics and, 216–218
premarket review proposal, 282–283
risk-based medical device classification, 279
risk-benefit analysis in, 134
waivers of consent and, 200–201
foresighting, anticipatory knowledge and, 285–286
forms of engagement, health regulation research and, 14
for-profit health research, benefit sharing and, 154–156
Foucault, Michel, 163, 383
foundational research tools, non-exclusive research tool licensing, 142–143
Four Principles, 169–170
14-day rule
embryo research and, 365–372
evolution of, 366–368
grounds for revisiting, 370–372
in HFE ACT, 367
special status principle and, 367–370
theoretical basis for, 368–370
Franklin, Benjamin, 220–221
free riders argument, enforceability of solidarity and, 58–59
Frewer, L. J., 114
Fricker, Miranda, 90nn.1–2
Friedman, Marilyn, 31
Friesen, Phoebe, 202, 299
Fukushima disaster, emergency healthcare and, 319–320
functional complementarity, 264
Fung, A., 124–125, 127–129

Gallagher, N., 118
Ganguli-Mitra, Agomoni, 92–93, 275–276, 315–323
Gash, A., 124–125, 128–129
gastrulation, human embryo research and, 368–370
Gelsinger, Jesse, 222
gender equity
autonomy and, 31
benefit sharing and marginalisation of, 152–156
medical device failure and marginalisation of, 162–165
physical integrity and identity and, 385–386
reproductive medicine and, 354–355
Gene Editing Summits, 335–336
gene-editing techniques, balancing of interests and, 267–268
General Data Protection Regulation (GDPR, EU), 67–70, 167–169, 171, 243–245
procedural complementarity in, 264
General Guidelines for the Research of Non-Conventional Medicines (WHO), 299–301
General Medical Council (GMC), 377–381
general public, classification of, 117
gene therapy research, 222
genetics research
Argentinian genetically modified crops, 324–325
co-dependent human-technology embodiment and, 383–384
cultural protections and, 242n.23
group vulnerability and, 95–97
harmonization of regulations on, 341–343
human gene editing, 335–343
interspecies research, 356–364
risk identification in, 130–132
genomic initiatives, 103–104
co-dependent human-technology embodiment and, 383–384
disclosure of research findings and, 231–234
ethical licensing for, 145–146
human genome definitions in, 346–348
normative systems regulation, 336–341
participants' interest in, 234–235
probabilistic *vs.* predictive results in, 232–233
regulation of, 267–268
Genomics England initiative, 6, 103–104
Genotype/Phenotype database (dbGaP), 193
Ghinea, Narcyz, 287–295
Giddens, Anthony, 257
Global Alliance for Genomics and Health, 103–104, 195
Global Code of Conduct for Research in Resource-Poor Settings, 152
global health emergency research (GHER)
data sharing in, 87–89
emergency context in, 316–317
future issues and challenges in, 322–323
governance and oversight guidelines and practices, 320–322
justification for, 318–320
social value and ethics in, 51–52
trustworthy institutions in, 81–89
global non-autonomy, situational vulnerability and, 33
Glover, Anne (Dr.), 222–223
Good Clinical Practice (WHO), 152
Good Clinical Practice Guidelines (ICH), 105–106, 173–175
good will, trust and, 84
Google Deep Minds' health data processing project, 118–119
Gotze, J., 119–120
Governance Arrangements for Research Ethics Committees (GafREC), 179
governance of research. *See also* participatory governance
adaptive governance, Big Data research regulation, 257–265
Argentinian cell therapy research, 325–326
benefit sharing and, 151–153
data governance frameworks, 59–61, 187–196
data subject rights, 188–189
defined, 257
ethical approvals process and, 307–309
genomics research, normative framework in, 336–341
global health emergency research, 320–322
health research regulation and, 1–2, 14
implementation of effective models, 260–263
inefficiencies in, 202

innovation oversight and, 292–295
institutional dimensions of health research and, 205–214
international health policy frameworks and, 340–341
learned and academic societies as experts for, 218–220
national policy frameworks for genetics and, 337–340
in neuroscience, 304, 310–312
patent regulation and, 141–142
principles-based regulation and, 257–259
privacy and, 77–80
public engagement and, 119–120
rule, principles and guidance-based initiatives, 167–176
structures and processes, 263–265
trustworthiness of, 248–249
group-level solidarity, 58–59
health research and, 59–61
groups
common interest and privacy of, 241–243
legal privacy protection for, 243–246
risk identification in research on, 130–132
vulnerability in health research for, 93–95
Guerrini, Christi, 145–146
Guideline 20 (CIOMS), 320–322
Guidelines for Human Experimentation (Germany), 17–18
Guidelines for Methodologies on Research and Evaluation of Traditional Medicine (WHO), 297–298
Guidelines for Trustworthy AI (European Commission), 175
Gusterson, Hugh, 285–286

H3Africa benefit sharing initiative, 153
Haas, Nayeli Urquiza, 296–305
Habets, M., 53–54
Hacking, Ian, 285–286
Hancock, Matt, 271
harm
artificial intelligence and prevention of, 271
automated healthcare and, 266–274
in Big Data research, 123
expectations and failure involving, 160–162
future harm, prevention of, 158–166
in global crisis emergencies, 317–318
group vulnerability and, 97
proportionality of, 39–40
risk identification and, 130–132
social value and, 54
systemic causes of, 162–165
Harmon, Shawn H. E., 382–390
harmonization of regulation, genetics research and, 341–343
Harper, Steven, 216–218
Hastings Center Report, social value in, 51–52
Havasupai tribe, 138
health research on, 130–132
protection for, 242n.23
Hawley, K. J., 88n.45
Health and Care Act 2012 (UK), 301–302
healthcare
access to, 59–62, 154–156
automated healthcare, 266–274
disclosure of research findings and, 231–234
failure of care data, 69–70
regulatory regimes *vs.*, 6
research and, 6
research-therapy divide in technology governance and, 277–286
resistance to participatory governance in, 125
health research, value-driving paradigm for, 394–396
Health Research Authority (HRA) (UK), 205
Confidentiality Advisory Group (CAG), 212–213
institutional overview of, 208–209
Proportionate Review Service, 182–184
public interest guidelines, 67–70
health research regulation
Argentinian advanced therapies research, 324–331
automated healthcare, 266–274
benefit sharing and, 148–157
best practices and, 173–175
clinical innovation and barrier of, 287–290
countervailing trends inf, 201–202
current and future trends in, 197–203
design innovations in, 182–184
disclosure of findings, protocols for, 229–238
evaluation of changes to, 202–203
expert and advisory advice in, 215–224, 248–256
failure in, 158–166
future issues for, 222–224
human embryo research, 365–372
human gene editing, 335–343
human germline research, 350–352
institutional influence in, 205–214
interspecies research and, 356–364
key concepts in, 13–15
learned and academic societies' influence on, 218–220
of medical devices, 277–286, 382–390
in neuroscience research, 304
non-evidence based reproductive medicine and, 373–381
patent regulation, 139–147
policy advice sources in, 215–224
privacy and public interest in, 239–247
problems and issues with, 1–3
process simplification and harmonisation and, 200–201
public interest appeals in, 66–67
recent changes in, 3–5
responsive regulation development, 333–334
review as regulatory process and, 178–180
risk-benefit analysis in, 130–138
rule, principles and guidance-based initiatives, 167–176
shared practices in, 59–61
software as medical device and, 277–286
solidarity in, 56–64
supplementary guidance and, 173–175
traditional and non-conventional medicines, 296–305
visibility of, 264–265
health research systems
informed consent and evolution of, 103–104
participatory governance in, 123–126
health systems research, social value in, 51–52
He Jiankui, 345–346, 351, 354–355

https://doi.org/10.1017/9781108620024.049 Published online by Cambridge University Press

Held, V. P., 240
Heller, Michael, 141
hematopoietic progenitor cells (HPC), Argentinian regulation of research on, 326–328
Hendl, Tereza, 287–295
Heneghan, Carl J., 160–161
High Level Expert Group (HLEG), 7–8
Hilgartner, Stephen, 139
Hinterberger, Amy, 356–364
Hirsch Index, 47–49
historical influences, institutional decision-making and, 212–213
Ho, Calvin W. L., 277–286
Hodgson, G. M., 207–208
Hoffmann (Lord), 245–246
homeopathic practices, guidelines for, 301–302
homogeneity
  of institutions, 213
  vulnerability and, 33–34
Horizon Programme, 152
human assemblage ideology, human-technology embodiment and, 384–386
human-centric governance, automated healthcare regulation and, 272
human challenge trials, debate over, 318–320
human embryo research
  admixed embryos, 358–359
  evolution of regulatory framework for, 366–368
  14-day rule and, 365–366
  interspecies research and, 356–364
  regulation of research on, 365–372
  revisiting 14-day rule in, 370–372
  special status principle in, 367–368
  terminology and definitions of, 347–348
  threshold of humanity principle and, 370–372
Human Fertilisation and Embryology Act and Authority, HFEA (1990, UK)
  Code of Practice, 378–379
  data protection regulation in, 171
  human embryo research and, 358–359, 365–368
  human germline research and, 346–350
  reproductive immunology warning and, 376–377
  reproductive medicine add-on services and, 378–379
  revisions to, 368–370
  in vitro fertilisation licensing and, 374
human gene editing
  harmonization of regulations on, 341–343
  international health policy frameworks and, 340–341
  moral concerns over, 336–341
  national policy frameworks for, 337–340
  normative regulatory systems for, 335–343
  slippery slope ideology and, 349–350
Human Genome Organization (HUGO), 149–151
Human Genome Project, 103–104
  open access and, 190–191
human germline research
  context in, 348–350
  ethical debates over, 344–355
  future research challenges in, 354–355
  global regulation and scientific justice, 352–353
  harmonization of regulations on, 341–343
  international health policy frameworks and, 340–341
  national policy frameworks for, 337–340
  normative regulatory framework for, 336–341
  overview, 345–346
  regulation, responsibility and cooperative research in, 350–352
  terminology and definitions, 346–348
humanitarian crises
  health care regulation and, 199
  research ethics in, 315–323
  social value of research in, 317–318
humanity, threshold of
  enhancement innovations and, 383
  human embryo research and, 370–372
Human Medicines Regulations 2012 (UK), 377–379
Human Reproductive Cloning Act (2001, US), 347–348
human rights
  automated healthcare regulation and, 270
  disclosure of research findings and, 233–234
  duty of confidence and, 246
  genetics research regulation and, 340–341
  human embryo research and, 366–368
  identity as human right, 390n.49
  privacy as, 74–75
Human Rights Act 1998 (UK), 245–246
Human Tissue Act 2004, 212–213
Human Tissue Authority, 205
human values, health research regulation and, 7
Hunt, Matthew, 315–323
Hurricane Katrina, distrust of government response in, 319–320
Hurst, S. A., 21–22, 25
Hutter, B., 161–162
hypothesis-driven trials, social value of, 54
Hyun, Insoo, 361

idem principle of identity, 384–386
identity
  disclosure of research findings and, 229–238
  human-technology embodiment and, 384–386
  narrative as, health research participation and, 235–236
  right to, 390n.49
IDx-DR AI diagnostic system, risk assessment and market approval, 278–284
IMDRF (International Medical Device Regulators Forum), software as medical device regulations and, 282–283
Immergut, E., 208
incidental research findings, 229–230
  in neuroscience research, 309–310, 313
inclusiveness
  in health research governance, 259–260
  non-invasive prenatal testing and, 267–268
inclusive public engagement
  data intensive health research and, 118–119
  public expertise and, 251–253
incommensurability, proportionality and, 41–42
independent, interdisciplinary data access, 193–194
independent review boards, privacy and, 75–77

Indian Ocean tsunami, emergency healthcare and, 317–320
indirect benefit, in RCTs, 133
individuals and individualism
  autonomy guidelines in research ethics and, 29–30
  data governance and, 59–61
  group vulnerability and, 95–96
  health research regulation and, 7, 14
  individual vulnerability in research, 92–93
  institutional decision-making and role of, 211
informational privacy, 75
  data protection and, 75–77
  risks to, 130
information technology, collaborative licensing, 144–145
informed consent
  alternate models of, 200–201
  basis for, 104–105
  in Big Data research, 123
  consent to contact policies and, 201–202
  cultural factors in, 242n.23
  data protection and, 67n.15
  digital consent mechanisms and, 110
  evolution of health research and, 103–104
  fetishisation of, 181–182
  group vulnerability and, 95–96
  legal requirements for, 105–108
  limitations of, 108–109
  overview of, 103
  privacy and, 75–77
  proportionality and, 40
  relational autonomy and, 30–31, 34–36
  right of refusal and, 108
  solidarity in health research and, 59–61
  trust and, 248–249
  vulnerability and, 17–18, 20–22
  waivers of, 199–200
  written forms of, 108–109
infrastructural vulnerability, health research regulation and, 396, 23–24
inherent vulnerability, 33
innovative health research
  autologous mesenchymal stem cell intervention, 290–292
  clinical innovation in medical marketplace, 287–295
  collaborative licensing and, 144–145
  conflicts of interest in, 292–295
  disturbance of regulation from, 382–383
  emerging science and technology oversight and, 397–399
  enhancement innovations, 383–384
  ethical licensing and, 145–146
  government intervention and, 141–142
  market forces and, 140–141, 292–295
  medical device regulation and, 386–389
  national policy frameworks for genetics and, 337–340
  oversight and, 287–290, 292–295
  overuse of non-evidenced based therapies, 292–295
  patent regulation and, 139–147
  patent rights and, 141
  self-regulatory patent rights models and, 142–146
Institute of Medicine (IOM, US), 124, 391–394
Institutional Animal Care and Use Committee (IACUC), 360
institutional capture, public engagement and, 118–119
institutional review boards (IRBs)
  design and performance criticism of, 180–181
  purpose of, 177–178
  risk-benefit analysis and, 137–138
  single board (sIRB), 200–201
institutions
  accountability and risk aversion issues in, 211
  context of, 207–208
  decision-making body objectives in, 208–209
  decision-making body structure and composition, 209–211
  defined, 207–208
  design of, participatory governance and, 127–129
  health research regulation and, 14–15, 205–214
  influences on decision-making in, 208–213
  inter-institutional influences in, 213
  path dependencies and historical influences in, 212–213
  public *vs.* private duties in, 211
  solidarity of, health research and, 59–61
  trust in, 86–87
instrumentality, public engagement and, 113–116
integrity, human-technology embodiment and, 384–386
intellectual property rights
  collaborative licensing and, 144–145
  patent regulation and, 140–141
intended research findings, 229–230
interconnectedness
  in health research regulation, 2
  learning healthcare systems and, 391–394
inter-institutional design
  health research regulation and, 213
  learning healthcare systems and, 391–394
Interministerial Commission for Research and Medicaments of Advanced Therapies (Argentina), 328–329
internal validity, in RCTs, 133
International Bioethics Committee (UNESCO), 340–341
International Cancer Genome Consortium/25K Initiative, 193
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 105–106
International Covenant on Civil and Political Rights (UN), 105–106
International Ethical Guidelines for Health-related Research, 46–47
International Ethical Guidelines for Health-Related Research Involving Humans (CIOMS), 35–36, 46–47, 169, 199–200
international health policies
  genetics research regulation and, 340–341
  human germline research, 352–353
International Organization for Standards (ISO), 167–168, 282–283
interpersonal solidarity, 58–59
interpretive community, 210
  disclosure of research findings and, 236–238

interspecies biomedical research
chimeric organisms, 357–358
regulation of, 356–364
shifting regulatory boundaries in, 362–363
vulnerability issues, 363–364
interventions
autologous mesenchymal stem cell case study, 290–292
clinical innovation oversight and, 287–290
component risk-benefit analysis, 135–136
risk identification in, 130–132
social value of, 49–51, 53–54
in vitro fertilisation add-on procedures, 375–377
intrauterine culture, absence of effectiveness research on, 379
investigational therapeutics, global health emergencies and use of, 319
In Vitro Diagnostic Medical Devices Regulation (IVDR), 382–383, 386–389
in vitro fertilisation (IVF)
add-on procedures in, 375–377
costs of, 375
culturing technological advances in, 368–370, 373–374
failure rate in, 375–377
14-day rule and, 365–366
non-evidence-based medicine in, 373–381
patient choice dynamics in, 380
special status principle in, 367–368
threshold of humanity principle in, 370–372
time pressures in, 374–377
Warnock Report findings and, 366–368
ipse principle of identity, 384–386
Isasi, Rosario, 335–343
isomorphism
institutional decision-making and, 210
inter-institutional influences and, 213
issue characteristics, rare disease research, 61–62

Jackson, Emily, 373–381
Jacobs, Marie Andree, 304
Jasanoff, Sheila, 306–307
Johnson, Summer, 218
justice
autonomy guidelines and, 27–29
as benefit sharing argument, 150–151, 154–156
human germline research, 352–353
informed consent and, 104–105
medical device failure and, 162–165

Kant, Immanuel, 78–79
Kaye, Jane, 103–111
Kerasidou, Angeliki, 14–15, 81–89
Kerridge, Ian, 287–295
Kieslich, Katharina, 14, 56–64
Kipnis, K., 396, 23–24
Klitzman, R., 203
Knight, D., 159–160
knowledge production
failure as tool for, 162–165
medical device failure and organisation of, 162–165
participatory government and forms of, 126–127
participatory health governance and, 285–286
risk-benefit analysis and, 132–134
Koops, Bert-Jaap, 273
Kurunmäki and Miller, 159

labelling approach, vulnerability research and, 20–22
ladder of public participation, 114, 116
Lane, Neal, 223–224
Lange, M. Meeke, 23–24
Langwick, Stacey, 304
Laurie, Graeme, 1–10, 165, 264–265, 277–278, 285–286, 391–400
laws and legislation
Argentinian health research regulation and, 330–331
data protection law, 243–245
fetishisation of consent and, 181–182
genomics research and, 336–341
group privacy protections and, 243–246
human embryo special status in, 367–368
informed consent and, 108–109
institutional decision-making and, 212–213
medical device regulation and, 388–389
physical integrity and identity in, 385–386
politics and barriers to, 223
privacy and, 241–243
public interest and, 67–70
shifting regulatory boundaries in animal research and, 362–363
traditional and non-conventional medicines and, 303–304
leadership support, participatory governance and, 127–129
learning healthcare systems
continuous learning and research-therapy divide in, 277–286
current and future trends in, 199
disclosure of research findings and, 231–234
minimal risk principle and, 199–200
patient engagement in, 124
regulatory science and, 391–394
risk identification in, 130–132
Learning Health Research Regulation System (LHRRS)
basic goals and features of, 399–400
ecosystem for, 397–399
learning healthcare systems and regulatory science and, 391–394
overview of, 1–10
proposals for, 5, 391–400
value and social values in, 394–396
legitimacy
medical device failure and, 163–164
of public engagement, 250–251
public interests and, 240–241
Lemley, Mark, 140–141
Leopoldina Society, 218, 220
licensing
collaborative licensing, 144–145
ethical licensing, 145–146
mixed licensing models, 143–144
non-exclusive research tool licensing, 142–143
reproductive medicine add-on services, 377–379

temporary licensing, 165
in vitro fertilisation and, 374
lifecyle assessment, software as medical device regulations and, 282–283
liminality
advisory bodies and, 221
AI/ML device regulation and, 278
artificial intelligence and, 277–278
health policy advice and, 215–216
health research regulation and, 222–224
Liminal Spaces Project, 3
emerging science and technology oversight and, 397–399
limited disclosure of information, informed consent and, 107
Lipworth, Wendy, 287–295
Lloyd-Bostock, S., 161–162
local governance reviews
global health emergencies and, 319–320
inefficiencies with, 202
Long Term Plan (NHS), 271
low-and-middle income countries (LIMC)
benefit sharing in, 152–156
biotechnology regulation in, 324–325
global health emergencies in, 317–318
regulatory thresholds in, 353
trust in health research in, 81–82, 85–86
vulnerability of groups in, 93–95
Lowi, Theodore, 61–62
Luna, F., 23–24
Lysagt, Tamra, 287–295

MacCormick, N., 208–209
machine learning
IDx-DR AI diagnostic system, 281–284
as medical device, 277–286
Mackenzie, Catriona, 32
maker movement, evolution of, 382–383
Managing Ethico-social, Technical and Administrative Issues in Data ACess (METADAC, UK), 126
March, J., 209–211
Margulis, S. T., 242
market forces
autologous mesenchymal stem cell case, 290–292
clinical innovation and, 287–295
medical device regulation and, 382–383, 386–389
overuse of non-evidenced based therapies and, 292–295
patent regulation and, 140–141
in reproductive medicine, 375–377
Markingham, Dan, 21
May, William, 178
Mayo Clinic Biobank deliberation, 125–126
McLeod, Carolyn, 32, 34–35
McMillan, Catriona, 333–334, 365–372
Medical Assistance in Dying and When Antibiotics Fail (CCA), 219–220
medical devices. *See also* software as medical device (SaMD)
artificial intelligence/machine learning as, 277–286
clinical trials for, 279–281
current and future regulation concepts and perspectives, 382–390
expectations for, 160–162
failure of, 158–166
future challenges in regulation of, 389–390
knowledge base for, 162–165
market forces in regulation of, 386–389
participatory learning in regulatory governance of, 284–285
post-market surveillance of, 388–389
re-embedded risk and sociality and, 281–284
risk-based FDA classification of, 279
temporary licensing for, 165
Medical Devices Regulation (MDR, EU), 161, 386–389
Medicines and Healthcare Products Regulatory Agency (UK), 205, 377–379
Médicins sans Frontières, 132–133
Medina, José, 35–36
Megan's Law, 285–286
mental health research, risk identification in, 130–132
Meslin, Eric M., 215–224
Mesmer, Anton, 220–221
METADAC (Managing Ethical, Sociotechinical and Administrative issues in Data Access), 193–196
metal-on-metal hips, expectations and failure involving, 160–162
MEURI (monitored emergency use of unregistered and experimental interventions) scheme, 319
Mexican General Health Law, 97
Mill, John Stuart, 78
Miller, Franklin, 235, 399–400
Millum, Joseph, 51–52
mimetic isomorphism, 213
minimal risk principle, health research regulation and, 199–200
mitochondrial replacement therapy (MRT)
emergence of, 344–345
terminology and definitions of, 347
mixed licensing models, patent regulation and, 143–144
Mode 2 research, social values and, 47–49
Moffett, A., 376
monitoring, in health research governance, 259–260
moral agency
automated healthcare regulation and, 273–274
global health emergencies and, 321–322
human-technology embodiment and, 384–386
trust and, 85
trustworthy institutions and, 86–87
moral hazard, mixed licensing model and, 143–144
multi-agency research networks
learning healthcare systems and, 391–394
participatory health systems governance and, 126
multi-disciplinary efforts
institutional decision-making and, 210–211
learning healthcare systems and, 391–394
multilevel engagement strategies, participatory governance and, 128
Munsie, Megan, 287–295
Murtagh, M. J., 126
my data phenomenon, health research regulation and, 8–9

Nabatchi, T., 254–255
Nagoya Protocol on Access and Benefit-Sharing, 149
narrative tools, research findings as, 235–236
National Academies of Sciences, Engineering and Medicine (NASEM, US), 219–220
National Academy of Science (NAS), chimera research guidelines, 359–362
National Administration of Drugs, Food and Medical Technology (ANMAT), 325–329
National Agency of Promotion of Science and Technology (ANPCYT, Argentina), 325–326
National Bioethics Advisory Commission (NBAC, US), 221–222
National Bioethics Advisory Commission (US), 151–152
National Commission for Agricultural Biotechnology (CONABIA) (Argentina), 324–325
National Consultative Committee on Ethics (France), 221
National Electronic Health Record System (NEHRS) (Australia), 118–119
National Health Service (NHS)
  fertility treatment funding in, 375
  non-conventional treatment regulation and, 301–302
  research ethics and, 179
National Institute for Health and Care Excellence (NICE, UK), 173–175, 301–302
  in vitro fertilisation guidelines in, 375
National Institute for Transplantation (INCUCAI, Argentina), 325–328
National Institutes of Health (NIH, US), 142–143
  chimeric research moratorium, 359–362
national policy frameworks, genetics research and, 337–340
National Statement on Ethical Conduct in Human Research (Australia NHMRC), 105–106
natural ecosystem, health regulation and role of, 268–269
natural killer cells, reproduction medicine and mythology about, 375–377
negative function, innovation oversight and, 292–295
net risk test, risk-benefit analysis and, 136–137
networks of actors, adaptive governance and, 263–265
neuroimaging techniques, ethical issues and, 307–309
neuroscience research
  ethics, governance and practice in, 304
  incidental findings in, 309–310, 313
'A New Pathway for the Regulation and Governance of Health Research' (AMS report), 3–4
New Zealand, evidence-informed health policy in, 216–218
NHS Act 2006, 167–168
  Section 251, 68
NHS Trusts, 205
NHSX (UK), 271
Nicholls, Stuart G., 197–203
Nickel, P. J., 23–24
Nicol, Dianne, 139–147
Nielsen, Jane, 139–147
non-assertion covenants, patent regulation, 145–146
non-conventional medicine
  history and evolution of, 296–298
  research regulation of, 296–305
  uncertainty of knowledges and practices and, 303–304
non-evidence based medicine, *in vitro* fertilisation and, 373–381
non-exclusive research tool licensing, patent rights and, 142–143
non-identifiable data, duty of confidence and, 246
non-invasive prenatal testing (NIPT), regulation of, 267–268
non-maleficence
  informed consent and, 104–105
  proportionality and, 40
normative rationales
  autonomy and, 32
  disclosure of research findings and, 233–234
  genomics research, 336–341
  human embryo research and challenges of, 366–370
  human gene editing regulations, 335–343
  incidental research findings and, 309–310
  learning healthcare systems and, 391–394
  in neuroscience research, 308–312
  normative isomorphism, 213
  normic diversity, 252–253
  principles-based regulation and, 259
  privacy protection and, 73–74
  public engagement and, 113–116
  rules- and principles-based regulation and, 169, 172–173
North, D., 207–208
Notice of Proposed Rule Making, 202–203
Nowotny, H., 48–49
Nuffield Council on Bioethics, 151–153, 221, 267–268, 320–322
Nuremberg Code, 17–18, 105–108, 169
Nuu-chahnulth people, genetics research and, 242n.23

Obama, Barack, 216–218
O'Doherty, Kieran C., 121–129
OECD Guidelines on the Protection of Privacy and Transborder Flows of Personal Data, 75–77
off-label use of medicines, reproductive medicine add-ons, 377–379
off-target humanised tissue, interspecies research and problem of, 360–361, 363–364
Olsen, J., 209–211
O'Mathuna, D., 321–322
100,000 Genomes project,231–235
O'Neill, Onora, 9, 248–249
Ontario Cancer Research Ethics Board (OCREB), 200–201
open data and open science
  data-driven research, 190–191
  disclosure of research findings and, 231–234
  health research regulation and, 8–9
  patent regulation and, 141–142
  trust and, 87–89
Opinion on Ethical Aspects of Clinical Research in Developing Countries (European Group on Ethics), 151–152
optimism bias, overuse of non-evidenced based therapies and, 292–295

organ donation/retention, regulations concerning, 212–213
Organisation for Economic Co-operation and Development (OECD), data governance and, 190–191
orphan drugs research
  societal reframing of, 63
  solidarity in, 61–63
Oshana, Marina, 31
Ostrom, Elinor, 262–264
Osuji, P., 108–109
outputs of health research, 100
over-inclusive labelling, vulnerability in research and, 21–22
Oviedo Convention, 105–106, 340–341

pain relief protocols, vulnerability and, 19
Pang, T., 124
participants in health research
  benefit sharing with, 154–156
  disclosure of research findings and, 229–238
  feedback to, 230
  interests of, disclosure guidelines and, 234–235
  in neuroscience research, 308
participatory governance. *See also* governance of research
  clinical innovation oversight and, 289–290
  enabling conditions for, 126–127
  health research regulation and, 99–101, 121–129
  health research systems, 123–126
  institutional designs for, 127–129
  international initiatives in, 124–125
participatory learning systems, regulatory governance and, 284–286
patent aggregation, 145
patent pledges, 145–146
patent pools, 144–145
patent rights and regulation
  benefit sharing principle and, 150–151
  ethical licensing, 145–146
  government intervention and, 141–142
  health research innovation and, 139–147
  mixed licensing models, 143–144
  non-exclusive research tool licensing, 142–143
  as private regulation, 140–141
  self-regulatory models for, 142–146
paternalism, vulnerability in research and, 22
path dependency, institutional decision-making and, 212–213
pathogenic vulnerability, 91
patient and public involvement (PPI). *See also* public engagement
  benefit treatment and, 54
  consumerist and democratic approaches to, 121–123
  disclosure of research findings and, 231–234
  health research regulation and, 46, 48–49, 250–251
  identity interests in, 397–399
  increased demand for, 70–71
  participatory governance in health research and, 121–129
patient-centered care, learning healthcare systems and, 391–394
Patient-Centered Outcomes Research Institute (POCRI, US), 126–127
patient choice dynamics, reproductive medicine regulation and, 380
patient health data
  consent to contact policies and, 201–202
  disclosure of research findings and role of, 233
  research regulations for use of, 167–168
Patient Network for Advanced Therapies (APTA Network, Argentina), 329
patterns of action, institutional decision-making and, 210–211
PAWORNET system (Riles), 284–285
perceptions of risk, risk-benefit analysis and, 134–135
performance of medical devices, research focus on, 162–165
permission to contact policies, 201–203
permissive function, innovation oversight and, 292–295
permitted embryo concept, 348–349n.26
personal data protection, privacy and, 75–77
Personal Genome Project, 103–104
pharmaceutical industry, solidarity-based research and, 62–63
placebo controls, evidence-based medicine and, 298–299
placental sampling, autonomy and consent to, 30–31
planned adaptations, research governance and, 264
policy formation in health research
  Delphi policy study, 397–399
  disclosure of research findings and, 229–238
  evidence and evidence gathering and, 216–218
  expert and advisory advice in, 215–224
  future issues in, 222–224
  genetics research regulation and, 336–341
  international policy frameworks and, 340–341
  learned and academic societies as experts for, 218–220
  national genetics research frameworks for, 337–340
  panaceas ideology in, 262–263
politics in health research
  anti-science politics and, 216–218
  group membership and, 95–96
  group vulnerability and, 93–95
  health research regulation and, 14–15
  human germline research and, 352–353
  individual vulnerability, 92–93
  interspecies biomedical research regulations and, 362–363
  non-traditional medicine and, 299
  patent regulation and, 140–141
  policy advice experts and advisory committees and, 215–224
  protection and, 97
  public expertise and, 251–252
  trustworthiness and, 248–249
  vulnerabilities and power in, 90–98
polycentricity, Big Data research and, 257–259
population groups
  data on, 118–119
  in health research regulation, 59–61
positive function, innovation oversight and, 292–295
Postan, Emily, 229–238

https://doi.org/10.1017/9781108620024.049 Published online by Cambridge University Press

posthumanism
enhancement innovations and, 383
identity and integrity issues and, 384–386
post-market surveillance, medical device regulation and, 388–389
post-trial obligations, benefit sharing and, 152–153
Potter, N. Nyquist, 84–85
poverty, vulnerability and, 92–93
Powell, W., 210
power
benefit sharing and role of, 154–156
definitions and analysis of, 90–91
group vulnerability and, 95–96
participatory governance and devolution of, 127–129
patent regulation and, 140–141
resource imbalance with, 126–127
trust and parity in, 85–86
vulnerabilities in health research politics and, 90–98
vulnerability and, 14–15
Prainsack, Barbara, 14, 56–64
precarity
in global crisis emergencies, 317–318
vulnerability and, 23–24
Precision Medicine Initiative (PMI, US), 103–104, 122–123
predictive influences, institutional decision-making in health regulation and, 208
pregnancy
non-invasive prenatal testing and, 267–268
in vitro fertilisation risks in, 375
vulnerability of, 20–22, 33–34
preparedness principles, in global health emergency research, 322–323
preponderance theory, public interest and, 240
prescriptive influences, institutional decision-making in health regulation and, 208
Prictor, Megan, 103–111
primary research, findings from, 229–230
primitive streak development, human embryo research and, 367–370
principles-based regulation
AFIRRM model and, 260–263
Big Data research, 257–259
development of, 169–172
health research regulation and, 167–176
limitations, 172–173
privacy
atomistic conception of, 241–243
in Big Data research, 123
data access governance and, 188–189
data protection law and, 243–245
defined, 241–243
duty of confidence and, 245–246
group privacy, 241–243
health research regulation and, 8–9, 14
as human right, 74–75
informed consent and, 75–77
legal protection of group privacy, 243–246
in modern context, 73
normativity of, 73–74
in personal data protection, 75–77
public interest and, 239–247
research governance and, 77–80
risk to violation of, 130
private sector healthcare
genomics research and, 336–341
learning healthcare systems and, 391–394
medical device regulation and, 386–389
misinformation about reproductive medicine and, 379
patents as, 140–141
reproductive medicine, 374, 377
procedural ambiguity, neuroscience research and, 310–312
procedural complementarity, 264
professionalised lay experts, participatory governance and, 127
Professional Standards Authority (PSA, UK), 301–302
progressive value, benefit analysis and, 53–54
proportionality
analytical complexities, 41–42
defined, 37–38
emerging science and technology oversight and, 397–399
in global health emergency research, 322–323
of harms, 39–40
health research regulation and, 13–15
procedural approaches to, 42–45
of review, 39–40
social value and, 40–41
protected experimental use, patent regulation and, 141–142
protection, politics in health research and, 97, 141–142
protocol risks, vulnerability of participants and, 21
Public Accountability for Health-Related Research, CIOMS guidelines and, 47–49
public engagement. *See also* patient and public involvement; patient and public involvement (PPI)
anti-science politics and, 216–218
consultation and, 115–116
critique in, 112–113
empowerment and, 116
evaluation of, 119–120
forms of, 113–116
global health emergencies and, 319–320
health research regulation and, 7, 99–101
human germline research and, 354–355
inclusive approach to, 118–119
layers of, 114–115
narrative of findings as tool for, 235–236
overview, 112
participatory learning in regulatory governance and, 284–285
public expertise mobilisation and, 248–256
representation and inclusiveness issues in, 251–253
trust and legitimacy challenges in, 250–251
trustworthiness of research governance and, 248–249
types of publics in, 117
public expertise, mobilization of
deliberation and, 253–255
health regulation research and, 14
public funding, patent regulation and, 141–142
Public Health England, Value of Vaccines campaign, 115
public interest

automated healthcare and balancing of, 267–268
CIOMS Public Engagement guidelines and, 47–49
common interests and, 240–241
contested concepts of, 65–66
data acceptability and, 70–71
data protection law and, 243–245
decision-making in, 211
deliberative public engagement and, 252–253
health research regulation and, 13–15
holistic concepts of, 71–72
as legal device, 67–70
privacy and, 78, 239–247
trust and legitimacy challenges in, 250–251
public-private models
genomics research regulation, 336–341
learning healthcare systems and, 391–394
public reason, public interest and, 240–241
pure public, classification of, 117

Quality-Adjusted Life Years, proportionality and social value, 40–41
Quality-Adjusted Time Without Symptoms and Toxicity (Q-TWIST) test, 138
Quality Management System (QMS), AI/ML medical device regulation and, 283–284
quandary ethics, medical device failure and, 163

Raab, C. D., 241–243
Rahmizadeh, V., 203
Rai, R., 376–377
randomised clinical trials (RCTs)
design in reproductive medicine for, 374–377
evidence-based medicine and, 298–299
global health emergency research and challenges of, 318–320
reproductive medicine and lack of, 373–374
risk-benefit analysis and, 132–134
range of sensitivities, privacy and, 79
rare disease research, solidarity in, 61–63
Rawls, John, 49, 78–79, 240n.7
Raz, Joseph, 31
REACH platform, 284–285
real-time responsiveness, global health emergencies and, 320–322
reasonable availability model, benefit sharing and, 152–153
reasonableness and reason-giving, diversity theory and, 252–253
reasonable risk, risk-benefit analysis and, 136–137
redundancy, Big Data research and, 257–259
Reed, Chris, 277–278
reflexivity, in health research governance, 259–260
refusal, informed consent and right of, 108
regenerative medicine
advanced therapies in, 324
Argentinian governance of research in, 325–326
regulation and oversight of, 359–362
vulnerability issues in, 363–364
registrant risk assessment scale (RRAS), 285–286
regulatory committees, institutional context for, 205
regulatory/governance approach (RGA)
AI/ML medical devices and, 281–284
to health research, 167–168
participatory learning systems and, 284–286
regulatory lapse, emerging technologies and, 167–168
regulatory regimes
clinical care vs., 6
clinical innovation oversight and, 289
inefficiencies in committees, 201–202
innovation oversight and, 292–295
medical devices and changes in, 279–281
recent challenges for, 4–5
regulatory responsibility
automated healthcare regulation and, 271–274
human germline research, 350–352
regulatory science, learning healthcare systems and, 391–394
relational autonomy
informed consent and, 34–36
participatory governance and, 127–129
principles of, 30–33
vulnerability and, 33–34
reliability, trustworthiness and, 88n.45
Reliable Replacement Warhead (RRW) program, 285–286
reliance, trust in global health research and, 85–86
representation and representativeness
group vulnerability and, 95–96
participatory governance and, 126–127
in public engagement, 251–253
representative diversity, 252–253
reproductive autonomy, non-invasive prenatal testing and, 267–268
reproductive immunology
lack of research and regulation of, 375–377
off-label use of, 377–379
reproductive medicine. *See also* cloning
add-on services regulation in, 377–379
alternative treatments in, 375–377
context in research on, 348–350
disclosure guidance in, 231, 233–234
evolution of regulatory framework for, 366–368
14-day rule and, 365–372
global regulations and policies and, 352, 354–355
human gene editing and, 267–268, 336–341
innovation oversight in, 292–295
non-evidence-based medicine in, 373–381
patient choice dynamics in, 380
pre-implantation genetic diagnosis and, 336–341
risks of add-ons in, 380–381
threshold of humanity principle in, 370–372
researchers ethical capacities, global health emergencies and, 321–322
research ethics boards (REBs)
purpose of, 177–178
risk-benefit analysis and, 137–138
research ethics committees (RECs), 46
design and performance criticism of, 180–181
fetishisation of consent and, 181–182
future directions for, 184–185
innovation oversight and, 292–295
neuroscience research and, 304

research ethics committees (RECs) (cont.)
purpose of, 177–178
regulatory role of, 178–180
risk-benefit analysis and, 137–138
social value and, 52–53
standardisation of procedures for, 182–184
Research Involving People Living in Developing Countries: Position Statement and Guidance Notes for Applicants (Wellcome Trust), 151
research-therapy divide, continuous learning systems and, 277–286
Resnik, D. B., 52
resource/power imbalance, participatory governance and, 126–127
respect for persons, autonomy guidelines and, 27–29
responsiveness, in health research governance, 259–260
review, proportionality of, 39–40
revisionism, scientific claims and, 49
Richardson, Megan, 246
Richert, Lucas, 303–304
Rid, A., 49–52, 71–72
The Right to Privacy (Richardson), 246
right to try principle
clinical innovation and, 288–289
misinformation about reproductive medicine and, 379
rigorous justification, proportionality and, 43
Rijke, J., 263
Riles, Annelise, 284–285
Rip, A., 159–160
risk
defined, 130
failure in health research and, 158–166
in health research governance, 259–260
identification of, 130–132
institutional aversion to, 211
medical device classification based on, 279
re-embedded risk in medical devices, 281–284
of reproductive add-on treatments, 380–381
SaMD risk characterization framework, 282–283
social value of research and, 199–200
risk-benefit analysis
benefits identification, 132–134
disclosure of research findings and, 230–231
first-order proportionality and, 37–38
in health research regulation, 130–138
health research regulation and, 14
medical devices and, 160–162
methodologies for, 135–137
procedural issues, 137–138
public interest and role of, 250–251
quantification of, 134–135
risk identification in, 130–132
risk object designation
AI/ML algorithm and, 279–281
medical device regulation and, 386–389
re-embedded risk and sociality and, 281–284
regulatory governance and, 285–286
software as medical device, 277–278
Robertson, John, 178
Roche, Ellen, 21
Rogers, Wendy A., 13, 17–26
Rose v. Secretary of State for Health, 385–386
Rowe, G., 114
Royal Academy of Sciences, 218
Royal Society (UK), 218, 220
Royal Society of Canada, 219–220
Rudge, Chris, 287–295
rules-based approaches (RBAs)
automated healthcare regulation and, 270–271
development of, 169–172
health research regulation and, 167–176
limitations, 172–173
R (Source Informatics) v. Department of Health, 246
R (W,X,Y and Z) v. Secretary of State for Health (2015), 245–246

safety
expectations and failure involving, 160–162
of traditional medicine, research on, 299–301
Salter, B., 288–289
Schaefer, Gerald Owen, 13–14
Schulz, S., 112–113, 117
science and technology studies (STS)
health research regulation in, 48–49
public engagement in, 112–113
traditional and non-conventional medicines and, 303–304
scientific truth
health policy and, 217
negotiation and agreement over, 49
scientific uncertainty, risk-benefit analysis and, 134–135
secondary research
findings from, 229–230
institutional decision-making on, 212–213
regulation of, 199–200
second-order proportionality, defined, 37–38
security, data access governance and, 188–189
self-development, automated healthcare regulation and, 273
self-narrative, health research participation and, 235–236
self-regarding attitudes, relational autonomy and, 32
self-trust, relational autonomy, 32
semi-autonomous consent, 110
sequencing, in health research regulation, 395–396
Serwadda, D., 87–89
Seth, Nayha, 99–101, 167–176
Sherkow, Jacob, 141–142
Shreve, N., 376
Simm, Kadri, 148–157
single institutional review board (sIRB), proposals for, 200–201
situational vulnerability, 33
slippery slope ideology, human germline research and, 349–350
social conditions
adaptive governance and, 262–263
Big Data research and, 123
relational autonomy and, 31
social learning, adaptive governance and, 263–265
social practices of healing, 299–301

social value
application of, 52–55
automated health regulation and, 270–271
benefit analysis and, 53–54
benefit evaluation and, 54
benefit treatment and, 54
decision-making and, 54
of global health emergency research, 317–318
global health emergency research and, 318–320
health research regulation and, 14, 46–55, 199–200, 268
meaning of, 49–51
proportionality and, 40–41
re-embedded risk in medical devices and, 281–284
scholarly debate on, 51–52
in sociology of science, 47–49
solidarity as, 58–59
values and, 49–51, 394–396
sociology of science
neuroscience research and, 306–307
social value in, 47–49
therapeutic interactions research, 299
soft law
on benefit sharing, 152
genomics research and, 336–341
software as medical device (SaMD)
IDx-DR AI diagnostic system, 278–281
regulation of, 277–278
risk characterization framework, 282–283
solidarity
applicability and adjustments in HHR and, 58–59
automated health regulation and, 270–271
as benefit sharing argument, 150–151
as community and system value, 58–59
in health research regulation, 14, 56–64
meaning of, 56–58
rare diseases and orphan drugs research and, 61–63
Somatic Gene and Engineered Cell Therapies (CCA), 219–220
somatic gene therapy, regulation of, 336–341
somatic/germline distinction, human germline research and, 350
Sorauf, F. J., 240
Sorbie, Annie, 14, 65–72
Spanish Agency for Medicaments, Argentinian collaboration with, 329
special vulnerability paradigm, 19–20
health research ethics and, 19–20
stakeholder engagement
automated health regulation and, 268–269
Big Data research and, 257–259
data protections and, 189
failure in health research and, 158–159
independent, interdisciplinary data access and, 193–194
marginalisation in vaginal mesh failure and, 162–165
principles-based approaches and, 171–172
value-driving paradigm for, 394–396
stare decisis, institutional decision-making and, 212–213
Stark, Laura, 178–179
stem cell research
Argentinian regulation of, 326–328
autologous mesenchymal stem cell case, 290–292
regulation and oversight of, 359–362
shifting regulatory boundaries in, 362–363
vulnerability issues in regulation of, 363–364
Stem Cell Research Oversight (SCRO) committees, interspecies research oversight, 360
stereotyping, in vulnerability research, 20–22
stewardship
ethics in health research and, 182–184
health research regulation and, 268, 397–399
participatory health research governance and, 124
Stewart, Cameron, 287–295
Stilgoe, J., 112
Stoljar, Natalie, 13, 27–36
study design and size, RCTs and, 133
subjectivity, public engagement and, 113–116
substantial equivalence principle, medical device risk and, 160–162
supplementary guidance, health research regulation, 173–175
surrogate licensing, patent regulation and, 141–142
systemic oversight
AFIRRM model and, 262
Big Data research and, 259–260
context in, 262
structures of governance and, 263
systems approach
participatory governance in health research and, 123–126
to research regulation, 4–5
system value, solidarity as, 58–59

Taylor, Mark, 68–69, 71–72, 239–247
technology
Argentinian regulation of, 324–325
automated healthcare, 266–274
automated healthcare regulation and, 270–271
collaborative licensing and, 144–145
disturbance of regulation from, 382–383
failure of, 158–166
health research regulation and, 99–101, 198–199
informed consent and evolution of, 103–104
non-exclusive research tool licensing and, 142–143
patent rights and innovation in, 141
regulatory lapse and, 167–168
regulatory responsibility and, 271–274
Tello, J. E., 123–124
temporary licensing, for medical devices, 165
ten Have, H., 91
Ter Muelen, Ruud, 58–59
Testlin, Henri, 218
theory-practice gaps, rule-based and practice-based health regulation and, 172–173
therapeutic misconception, benefit sharing and, 154–156
third-party risks, identification of, 130–132
Thompson, J., 127
threshold of humanity principle
enhancement innovations and, 383
human embryo research and, 370–372
Tietjens, Diana, 31

tokenism
  public engagement and, 118–119
  resistance to participatory governance and, 125
Tongan people, cultural protections for, 242n.23
tools for health research regulation, overview, 99–101
top-down public engagement, 112
Townsend, David, 14, 73–80
Traditional Chinese Medicine (TCM), 299–301, 303–304
Traditional Herbal Medicine Products (THMPD), European Directive on, 297–298
traditional medicine
  economics of clinical guidelines for, 301–302
  history and evolution of, 296–298
  integration and regulation as subordination, 299–301
  research regulation of, 296–305
  uncertainty of knowledges and practices and, 303–304
tragedy of the anticommons, 141
translational value
  benefit treatment and, 54
  hypothesis-driven trials, 54
transnational dynamics, human germline research and, 353
transparency
  in benefit sharing, 153–154
  in collaborative research, 82–83
  data across governance and, 189–190, 192
  informed consent and, 104–105
  proportionality and, 43
  public engagement and, 118–119
Trudeau, Justin, 216–218, 222–223
Trump, Donald, 220–223
trust
  automated health regulation and, 268–269
  in data sharing collaborations, 87–89
  global health emergencies and building of, 319–320
  in global health research, 81–89
  health research regulation and, 9, 222
  in institutions, 86–87
  Learning Health Research Regulation System and, 394–396
  participatory governance and, 127–129
  risk-benefit analysis and, 134–135
  trustworthiness and, 83–85, 248–249, 254–255
trustworthiness, public expertise and, 248–249, 254–255
Trustworthy Institutions in Global Health Research Collaborations, 14–15
Turner, Victor, 278
Tuskegee syphilis study, 28, 34–35

UK Biobank, 194–195
uncertainty
  governance and, 262–263
  in neuroscience research, 310–312
  traditional and non-conventional medicines and, 303–304
UN Declaration on Human Cloning, 340–341
Understanding Patient Data and National Health Service England report, 70–71, 394–396
undue inducement, benefit sharing and, 154–156
unitary theory, public interest and, 240
United Kingdom
  data protection law in, 243–245
  duty of confidence and privacy protection in, 245–246
  evidence-informed health policy in, 216–218
  interspecies biomedical research regulations in, 362–363
  medical device regulation in, 162–165
  research process simplification and harmonisation and, 200–201
United States
  patient and public involvement in health research in, 122–123, 126
  third-party risk protocols in, 130–132
Universal Declaration of Human Rights, 74–75
Universal Declaration on Bioethics and Human Rights (UNESCO), 152
Universal Declaration on the Human Genome and Human Rights (UNESCO), 340–341
universality, of vulnerability, 19
upper limit on permissible risk, risk-benefit analysis guidelines, 137

vaginal mesh
  expectations and failure involving, 160–162
  gender marginalisation of harm from, 162–165
validity in health research
  disclosure of findings criteria and, 231, 236–238
  external *vs.* internal validity, 133
values
  automated health regulation and, 270–271
  commonly-held value, public interest and, 240–241
  disclosure of research findings based on, 231, 236–238
  learning healthcare systems and, 391–394
  patent regulation and, 140–141
  social value and, 49–51, 394–396
Valverde, Mariana, 285–286
van Delden, Johannes JM, 14, 46–55
van der Graaf, Rieke, 14, 46–55
van Gannep, Arnold, 278, 389
van Lente, H., 159–160
virtuous action, global health emergencies and, 321–322
voluntariness
  disclosure of research findings criteria based on, 231, 236–238
  informed consent and, 104–108
  of trust, 84–85
vulnerability
  ambiguity in HRR and, 19–20
  benefit sharing and, 154–156
  definition and analysis of, 23–24, 90–91
  global health emergency guidelines and, 316–317
  of groups, 93–95
  health research regulation and, 13
  individuals' vulnerability, 92–93
  interspecies biomedical research and realignment of, 363–364
  labelling approaches to research on, 20–22
  layers of, 396, 23–24
  politics of health research and, 90–98

power and, 14–15
in rare disease research, 62
relational autonomy and, 33–34
in research ethics guidelines, 17–18
risk assessment and, 199–200
taxonomy, 24
trust and, 83–85
universal capacity and, 24–25

Wainwright, Steven, 313
Waldby, Catherine, 287–295
Warnock Committee of Inquiry into Human Fertilisation and Embryology, report by, 366–368
Warren, Mark, 251–252
Weijer, Charles, 46–47, 96
welfare state, enforceability of solidarity and, 58–59
Wellcome Trust
on benefit sharing, 151
Blueprint for Dynamic Oversight of Emerging Science and Technologies, 397–399
public interest and, 68–69
Understanding Patient Data initiative, 70–71
Wendler, D., 49–52
Wenner, Danielle, 51–52
Wertheimer, A., 52
Western Herbalism, 299–301
Whitton, Tess, 239–247
WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks, 173–175
Wiersma, Miriam, 287–295
Wilcox, D., 115–116
Willis, R., 119–120
Wilsdon, J., 119–120
Working Group on Disaster Research Ethics (WGDRE), 317–318
World Health Organization (WHO)
bioethics advisory committees and, 221
CIOMS collaboration with, 46–47, 59–61
global health emergency guidelines and, 320–322
Good Clinical Practice, 152
health practices guidelines, 173–175
health systems framework, 123–124
traditional medicine and, 296–301
World Medical Association (WMA), 103–104
Wright, E. O., 124–125, 127–129
Wrigley, A., 91, 97
written assessments, risk-benefit analysis and, 137–138
Wynne, B., 112–113

Yishai, Y., 125

Zhan, Mei, 303–304
Zhang, John, 346, 353
Zita West fertility clinic blog, 376–377